AstraZeneca Korea voluntarily withdrew approval for ‘Forxiga (dapagliflozin),’ an SGLT-2 inhibitor class diabetes treatment, and transferred the chronic heart failure·chronic kidney disease indication to its partnering company H.K. inno.N’s 'Dapa N.'

Due to this clever co-promotion strategy between AstraZeneca Korea and HK inno.N, the prescription market worth KRW 50 billion annually is expected to significantly shift. In particular, HK inno.N’s Dapa N, assuming the indication that no other generics have, is expected to become a dark horse in the SGLT-2 inhibitor market.

HK inno.N ‘Dapa N’ assumes the original indication…anticipated to expand its presence in the diabet

Kim, Jin-Gu(kjg@dailypharm.com)